Supernus Pharmaceuticals | SUPN - Pre Tax Profit


Supernus Pharmaceuticals reported $-5.95M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Abbott USD 2.39B 27M Mar/2026
ANI Pharmaceuticals USD 31.48M 18.04M Dec/2025
Aurora Cannabis CAD -1.58M 48.55M Dec/2025
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Canopy Growth CAD -62.26M 60.84M Dec/2025
Cara Therapeutics USD -4.91M 3.17M Mar/2025
Corcept Therapeutics USD 9.91M 5.33M Dec/2025
Eisai JPY -7.94B 29.94B Mar/2026
Eli Lilly USD 8.27B 1.03B Dec/2025
Novo Nordisk DKK 33.8B 3.23B Jun/2025
Pacira USD 571K 8.95M Dec/2025
Perrigo USD -1.33B 1.35B Dec/2025
Pfizer USD 5.18B 6.82B Mar/2026
Supernus Pharmaceuticals USD -5.95M 4.04M Mar/2026
United Therapeutics USD 444M 6M Dec/2025
Xeris Pharmaceuticals USD 11.08M 10.46M Dec/2025